Norman Ng: Advocating for Drug Price Disclosure and Transparency in Patient Care
Norman Ng, Director of Patient Advocacy and Public Affairs of Healthcare Thinkers, shared his earlier post on LinkedIn:
“Patient organizations should take “drug price disclosure” as the next important issue and actively promote it with relevant parties!
One of the speakers at the forum today once again raised the issue of price transparency:
The Importance of Information Transparency
– Patients should have access to more medication-related information, which is a worthy direction.
– It’s good to know that the Drug Office will provide more information in the future, such as public drug lists, etc.
Transparency in drug prices is key
– One of the most important pieces of information is the price of the drug.
– The resistance to price opacity is not from patients, the government or the HA, but from other aspects (worth pondering).
– Once the price of the drug is made public, the analysis of treatment costs and cost-effectiveness will naturally emerge.
Prerequisites for Cost-Benefit Analysis
– To discuss whether treatment is cost-effective, there must first be transparent information on drug prices.
– The price of drugs in the Mainland is open, and even the price of each pill is clearly stated, which is a practice worth referring to.
Patient Well-being and Pharmaceutical Responsibility
– If you value patients, information transparency, and patient well-being, you should take the initiative to disclose drug prices.
– Patient organizations should make “drug price disclosure” the next important issue and actively promote it with relevant parties.”
More posts featuring Norman Ng on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023